QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

$30.63
-0.38 (-1.23%)
(As of 03/4/2024 ET)
Today's Range
$29.85
$31.05
50-Day Range
$27.11
$31.08
52-Week Range
$21.99
$39.65
Volume
516,992 shs
Average Volume
352,339 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Supernus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.9% Upside
$41.00 Price Target
Short Interest
Bearish
7.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.23mentions of Supernus Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$374,330 Sold Last Quarter
Proj. Earnings Growth
17.78%
From $1.80 to $2.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.76 out of 5 stars

Medical Sector

253rd out of 960 stocks

Pharmaceutical Preparations Industry

118th out of 440 stocks


SUPN stock logo

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

SUPN Stock Price History

SUPN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Recap: Supernus Pharmaceuticals Q4 Earnings
SUPN Mar 2024 39.000 call
SUPN Mar 2024 28.000 put
SUPN Mar 2024 42.000 call
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. (SUPN)
3 Pharma Stocks to Buy Before Year-End
3 Rising Pharma Stocks to Consider Buying Now
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/04/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
612
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$41.00
Low Stock Price Target
$41.00
Potential Upside/Downside
+33.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$1.32 million
Pretax Margin
0.46%

Debt

Sales & Book Value

Annual Sales
$607.52 million
Cash Flow
$1.57 per share
Book Value
$16.87 per share

Miscellaneous

Free Float
49,940,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
0.97
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Jack A. Khattar (Age 63)
    Founder, President, CEO, Secretary & Director
    Comp: $1.63M
  • Mr. Timothy C. Dec (Age 65)
    Senior VP & CFO
    Comp: $635.43k
  • Dr. Padmanabh P. Bhatt Ph.D. (Age 67)
    Chief Scientific Officer & Senior VP of Intellectual Property
    Comp: $594.14k
  • Mr. Frank Mottola (Age 52)
    Senior Vice President of Quality, GMP Operations & Information Technology
    Comp: $490.87k
  • Dr. Jonathan Rubin M.D. (Age 63)
    MBA, Senior VP of Research & Development and Chief Medical Officer
    Comp: $594.65k
  • Mr. Kevin T. Anderson (Age 62)
    Compliance Officer
  • Dr. Todd Horich M.B.A.
    Ph.D., Senior Vice President of Marketing & Market Access
  • Mr. Taylor Raiford
    Senior Vice President of Sales
  • Dr. Bryan A. Roecklein Ph.D.
    Senior Vice President of Corporate Development
  • Ms. Tami T. Martin Esq. (Age 69)
    R.N., Senior Vice President of Regulatory Affairs
    Comp: $508.5k














SUPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price targets for Supernus Pharmaceuticals' shares. Their SUPN share price targets range from $41.00 to $41.00. On average, they predict the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2024?

Supernus Pharmaceuticals' stock was trading at $28.94 at the beginning of the year. Since then, SUPN stock has increased by 5.8% and is now trading at $30.63.
View the best growth stocks for 2024 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by $0.39. The specialty pharmaceutical company earned $164.30 million during the quarter, compared to analysts' expectations of $155.03 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 0.14% and a net margin of 0.22%. The firm's revenue was down 1.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$620.0 million, compared to the consensus revenue estimate of $622.5 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.38%), Armistice Capital LLC (8.51%), Dimensional Fund Advisors LP (4.50%), Stephens Investment Management Group LLC (3.49%), GW&K Investment Management LLC (2.41%) and Congress Asset Management Co. MA (1.68%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Jack A Khattar, Padmanabh P Bhatt and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SUPN) was last updated on 3/4/2024 by MarketBeat.com Staff